LIVIVO - Search results -

Search results

Result 1 - 10 of total 229

Search options

Article ; Online: COVID-19 and Disease-Modifying Anti-rheumatic Drugs.

D'Silva, Kristin M / Wallace, Zachary S

2021 Volume 23, Issue 5, Page(s) 28

Abstract: Purpose of review: Patients on disease-modifying anti-rheumatic drugs (DMARDs) remain concerned about potential risks of severe COVID-19 outcomes. Meanwhile, several DMARDs have been proposed as COVID-19 therapies.: Recent findings: In patients with ... ...

Abstract	Purpose of review: Patients on disease-modifying anti-rheumatic drugs (DMARDs) remain concerned about potential risks of severe COVID-19 outcomes. Meanwhile, several DMARDs have been proposed as COVID-19 therapies. Recent findings: In patients with autoimmune diseases, baseline glucocorticoid use is associated with severe COVID-19. While classes of DMARDs (e.g., conventional synthetic, targeted synthetic, and biologic) do not appear to be associated with higher risk, specific medications such as rituximab and sulfasalazine may be associated. Randomized clinical trials (RCTs) show that glucocorticoids reduce mortality in severe COVID-19. RCTs suggest other agents, such as baricitinib, may improve COVID-19 outcomes in certain populations. Baseline glucocorticoid use raises the risk of severe COVID-19 in patients with autoimmune diseases, but glucocorticoids are an effective treatment for those with severe COVID-19. Further research is needed to inform DMARD management in autoimmune disease patients during the pandemic and the role of DMARDs in COVID-19 treatment.
MeSH term(s)	Antirheumatic Agents/therapeutic use ; COVID-19/epidemiology ; Humans ; Pandemics ; SARS-CoV-2 ; COVID-19 Drug Treatment
Chemical Substances	Antirheumatic Agents
Language	English
Publishing date	2021-04-24
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Review
ZDB-ID	2057357-1
ISSN	1534-6307 ; 1523-3774
ISSN (online)	1534-6307
ISSN	1523-3774
DOI	10.1007/s11926-021-00998-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5531: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: COVID-19 and rheumatoid arthritis.

D'Silva, Kristin M / Wallace, Zachary S

Current opinion in rheumatology

2021 Volume 33, Issue 3, Page(s) 255–261

Abstract: Purpose of review: The coronavirus disease 2019 (COVID-19) pandemic has caused significant morbidity and mortality worldwide. Patients with rheumatoid arthritis (RA) face unique challenges during the pandemic, including concerns regarding infection risk, ...

Abstract	Purpose of review: The coronavirus disease 2019 (COVID-19) pandemic has caused significant morbidity and mortality worldwide. Patients with rheumatoid arthritis (RA) face unique challenges during the pandemic, including concerns regarding infection risk, drug shortages, limited access to care, social isolation, and mental health. This review will examine the multifaceted impacts of the COVID-19 pandemic on patients living with RA. Recent findings: In patients with RA, risk factors for severe COVID-19 outcomes include older age and comorbidities, similar to those in the general population. Glucocorticoids, but not other classes of disease-modifying antirheumatic drugs (DMARDs), appear to be associated with a higher risk of severe COVID-19 outcomes. RA patients have been affected by changes in access to care, telemedicine, drug shortages, anxiety, and social isolation, which may contribute to disease flares. Summary: Glucocorticoids, but not other DMARDs, are associated with a higher risk of severe COVID-19 outcomes in RA patients. Further studies are needed to explore the impact of specific DMARDs on COVID-19 outcomes, understand the broader implications of the COVID-19 pandemic on RA disease activity, and optimize the use of telemedicine in RA management.
MeSH term(s)	Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/drug therapy ; Arthritis, Rheumatoid/epidemiology ; COVID-19/epidemiology ; Comorbidity ; Glucocorticoids/therapeutic use ; Humans ; Pandemics ; Risk Factors ; SARS-CoV-2
Chemical Substances	Antirheumatic Agents ; Glucocorticoids
Language	English
Publishing date	2021-02-24
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1045317-9
ISSN	1531-6963 ; 1040-8711
ISSN (online)	1531-6963
ISSN	1040-8711
DOI	10.1097/BOR.0000000000000786
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3028: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Gender Differences in the Amount and Type of Student Participation During In-Person and Virtual Classes in Academic Medicine Learning Environments.

Cromer, Sara J / D'Silva, Kristin M / Phadke, Neelam A / Lord, Emma / Rigotti, Nancy A / Baer, Heather J

JAMA network open

2022 Volume 5, Issue 1, Page(s) e2143139

MeSH term(s)	Academic Medical Centers ; Adult ; Education, Distance/statistics & numerical data ; Education, Medical, Graduate/methods ; Education, Medical, Graduate/statistics & numerical data ; Female ; Humans ; Male ; Problem-Based Learning/statistics & numerical data ; Sex Factors ; Students, Medical/statistics & numerical data
Language	English
Publishing date	2022-01-04
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ISSN	2574-3805
ISSN (online)	2574-3805
DOI	10.1001/jamanetworkopen.2021.43139
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Incident systemic rheumatic disease following COVID-19.

Hsu, Tiffany Y-T / D'Silva, Kristin M / Patel, Naomi J / Fu, Xiaoqing / Wallace, Zachary S / Sparks, Jeffrey A

The Lancet. Rheumatology

2021 Volume 3, Issue 6, Page(s) e402–e404

Language	English
Publishing date	2021-04-06
Publishing country	England
Document type	Journal Article
ISSN	2665-9913
ISSN (online)	2665-9913
DOI	10.1016/S2665-9913(21)00106-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Systemic bevacizumab to facilitate anticoagulation in antiphospholipid syndrome and bleeding gastrointestinal angiodysplasia.

Cheloff, Abraham Z / Song, Andrew B / D'Silva, Kristin M / Al-Samkari, Hanny

Journal of thrombosis and thrombolysis

2021 Volume 53, Issue 3, Page(s) 708–711

Abstract: Bleeding gastrointestinal angiodysplasia may occur in patients with vasculitis and can be challenging to treat. We describe the novel use of bevacizumab therapy to treat bleeding gastrointestinal angiodysplasia and severe anemia in a patient with ... ...

Abstract	Bleeding gastrointestinal angiodysplasia may occur in patients with vasculitis and can be challenging to treat. We describe the novel use of bevacizumab therapy to treat bleeding gastrointestinal angiodysplasia and severe anemia in a patient with eosinophilic granulomatosis with angiitis complicated by antiphospholipid antibody syndrome requiring indefinite warfarin therapy. Studies confirmed multiple bleeding jejunal angiodysplasias unamenable to endoscopic intervention, and the patient required ongoing support with iron infusions and blood transfusions to maintain a minimally acceptable hemoglobin. Given the severe anemia, need for continued, indefinite antiplatelet and anticoagulation therapy, and failure of standard treatment approaches, the patient was initiated on systemic bevacizumab therapy, on the basis of prior documented success of bevacizumab to manage gastrointestinal telangiectasias in patients with hereditary hemorrhagic telangiectasia. Bevacizumab was highly effective, with rapid resolution of bleeding, normalization of hemoglobin, liberation from hematologic support and no adverse events, including no thromboembolic events. Vascular endothelial growth factor (VEGF-A) rose paradoxically after initiation of bevacizumab and normalized after its discontinuation. Given these findings, use of systemic bevacizumab to manage bleeding angiodysplasia in patients with acquired vascular disorders merits further study.
MeSH term(s)	Anemia ; Angiodysplasia/complications ; Angiodysplasia/drug therapy ; Anticoagulants/therapeutic use ; Antiphospholipid Syndrome/complications ; Antiphospholipid Syndrome/drug therapy ; Bevacizumab/therapeutic use ; Gastrointestinal Hemorrhage/drug therapy ; Gastrointestinal Hemorrhage/etiology ; Hemoglobins ; Hemorrhage/drug therapy ; Humans ; Vascular Endothelial Growth Factor A
Chemical Substances	Anticoagulants ; Hemoglobins ; Vascular Endothelial Growth Factor A ; Bevacizumab (2S9ZZM9Q9V)
Language	English
Publishing date	2021-10-25
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	1230645-9
ISSN	1573-742X ; 0929-5305
ISSN (online)	1573-742X
ISSN	0929-5305
DOI	10.1007/s11239-021-02590-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4352: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Increased Risk of COVID-19 in Patients With Rheumatoid Arthritis: A General Population-Based Cohort Study.

Wang, Yilun / D'Silva, Kristin M / Jorge, April M / Li, Xiaoxiao / Lyv, Houchen / Wei, Jie / Zeng, Chao / Lei, Guanghua / Zhang, Yuqing

Arthritis care & research

2022 Volume 74, Issue 5, Page(s) 741–747

Abstract: Objective: Patients with rheumatoid arthritis (RA) are at an increased risk of acquiring infections owing to immunologic dysfunction and use of potent immunomodulatory medications; however, few data are available on their risk of COVID-19. We estimated ... ...

Abstract	Objective: Patients with rheumatoid arthritis (RA) are at an increased risk of acquiring infections owing to immunologic dysfunction and use of potent immunomodulatory medications; however, few data are available on their risk of COVID-19. We estimated the rate of COVID-19 among RA participants and compared it with that of the general population. Methods: Using the Health Improvement Network, we identified RA patients before February 2020 and followed them to September 2020. We calculated the rate of COVID-19 among participants with RA and compared it with that of the general population using a Cox proportional hazards model, adjusting for potential confounders using overlap weighting of exposure score. We repeated the same analysis among participants with osteoarthritis, a nonautoimmune rheumatic disease, as a negative control exposure. Results: We identified 225 cases of suspected and confirmed COVID-19 among 17,268 RA patients, and 14,234 cases among 1,616,600 participants in the general population (1.4 versus 0.9/1,000 person-months), with the adjusted hazard ratio (HR Conclusion: RA, but not osteoarthritis, was associated with an increased risk of COVID-19. Our findings provide timely evidence to support recommendations that booster vaccines and priority access to anti-SARS-CoV-2 monoclonal antibody treatments should be encouraged for RA patients.
MeSH term(s)	Arthritis, Rheumatoid/complications ; Arthritis, Rheumatoid/diagnosis ; Arthritis, Rheumatoid/epidemiology ; COVID-19/epidemiology ; Cohort Studies ; Humans ; Osteoarthritis/complications ; Osteoarthritis/diagnosis ; Osteoarthritis/epidemiology ; Proportional Hazards Models
Language	English
Publishing date	2022-03-08
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	645059-3
ISSN	2151-4658 ; 0893-7524 ; 2151-464X
ISSN (online)	2151-4658
ISSN	0893-7524 ; 2151-464X
DOI	10.1002/acr.24831
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2446: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.A 24: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Transient blindness with periorbital erythema and swelling: Manifestations of recurrent systemic lupus erythematosus.

Hafeez, Farhaan / Gunasekera, Nicole S / D'Silva, Kristin M / Nazarian, Rosalynn M

JAAD case reports

2019 Volume 5, Issue 12, Page(s) 1088–1090

Language	English
Publishing date	2019-11-22
Publishing country	United States
Document type	Case Reports
ZDB-ID	2834220-3
ISSN	2352-5126
ISSN	2352-5126
DOI	10.1016/j.jdcr.2019.10.009
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Response to: 'Correspondence on 'SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease'' by C

D'Silva, Kristin M / Serling-Boyd, Naomi / Hsu, Tiffany Y-T / Sparks, Jeffrey A / Wallace, Zachary Scott

Annals of the rheumatic diseases

2021 Volume 82, Issue 6, Page(s) e131

MeSH term(s)	Humans ; SARS-CoV-2 ; COVID-19 ; Antibody Formation ; Rheumatic Diseases/complications ; Rituximab ; Vaccination
Chemical Substances	Rituximab (4F4X42SYQ6)
Language	English
Publishing date	2021-03-10
Publishing country	England
Document type	Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Letter ; Comment
ZDB-ID	7090-7
ISSN	1468-2060 ; 0003-4967
ISSN (online)	1468-2060
ISSN	0003-4967
DOI	10.1136/annrheumdis-2021-220166
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.114: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 167: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease.

D'Silva, Kristin M / Serling-Boyd, Naomi / Hsu, Tiffany Y-T / Sparks, Jeffrey A / Wallace, Zachary S

Annals of the rheumatic diseases

2021 Volume 80, Issue 6, Page(s) 817–819

MeSH term(s)	Antibodies, Viral ; Antibody Formation ; Antirheumatic Agents/therapeutic use ; Autoimmune Diseases ; COVID-19 ; Humans ; Rheumatic Diseases/complications ; Rheumatic Diseases/drug therapy ; SARS-CoV-2
Chemical Substances	Antibodies, Viral ; Antirheumatic Agents
Language	English
Publishing date	2021-01-12
Publishing country	England
Document type	Letter ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
ZDB-ID	7090-7
ISSN	1468-2060 ; 0003-4967
ISSN (online)	1468-2060
ISSN	0003-4967
DOI	10.1136/annrheumdis-2020-219808
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.114: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 167: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Risk of Incident Atrial Fibrillation With Zoledronic Acid Versus Denosumab: A Propensity Score-Matched Cohort Study.

D'Silva, Kristin M / Cromer, Sara Jane / Yu, Elaine W / Fischer, Michael / Kim, Seoyoung C

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

2020 Volume 36, Issue 1, Page(s) 52–60

Abstract: Zoledronic acid (ZA) is an effective agent in osteoporosis and malignancy-related bone disease but may be associated with increased risk of atrial fibrillation (AF), although current studies disagree on this risk. To examine the risk of incident AF among ...

Abstract	Zoledronic acid (ZA) is an effective agent in osteoporosis and malignancy-related bone disease but may be associated with increased risk of atrial fibrillation (AF), although current studies disagree on this risk. To examine the risk of incident AF among patients receiving ZA compared with denosumab in the first year of treatment, we performed a new-user, active comparator cohort study including privately insured Americans between January 1, 2010, and June 30, 2019. Individuals aged ≥50 years without known arrhythmia or advanced kidney disease who initiated ZA were 1:1 propensity score (PS)-matched to individuals initiating denosumab in separate osteoporosis and malignancy cohorts. The primary outcome was incident diagnosis of AF (≥1 inpatient or ≥2 outpatient diagnostic codes) over 1 year. Secondary outcomes included stroke/transient ischemic attack (TIA) and nonvertebral fracture. In the osteoporosis cohort (n = 16,235 pairs), mean age was 71 years, and 93% were female. There was higher risk of AF with ZA compared with denosumab over 1 year (incidence rate [IR] = 18.6 versus 14.9 per 1000 person-years; hazard ratio [HR] = 1.25; 95% confidence interval [CI] 1.04 to 1.50). In the malignancy cohort (n = 7732 pairs), mean age was 70 years, and 66% were female. There was a numerically higher, albeit not statistically significant, risk of AF with ZA compared with denosumab over 1 year (IR = 46.9 versus 39.0 per 1000 person-years; HR = 1.19; 95% CI 1.00 to 1.43; p = 0.06). No difference in stroke/TIA rates occurred. In the malignancy cohort, ZA was less effective than denosumab at preventing nonvertebral fractures (HR = 1.32; 95% CI 1.01 to 1.74). Compared with denosumab, ZA treatment for osteoporosis and possibly for malignancy-related bone disease is associated with modestly increased risk of incident AF in the first year of treatment. © 2020 American Society for Bone and Mineral Research (ASBMR).
MeSH term(s)	Atrial Fibrillation/drug therapy ; Atrial Fibrillation/epidemiology ; Bone Density Conservation Agents/therapeutic use ; Cohort Studies ; Denosumab/adverse effects ; Female ; Humans ; Propensity Score ; Zoledronic Acid
Chemical Substances	Bone Density Conservation Agents ; Denosumab (4EQZ6YO2HI) ; Zoledronic Acid (6XC1PAD3KF)
Language	English
Publishing date	2020-11-02
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	632783-7
ISSN	1523-4681 ; 0884-0431
ISSN (online)	1523-4681
ISSN	0884-0431
DOI	10.1002/jbmr.4174
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2142: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito